蛋白质组学指导的生物标志物发现、验证及通路扰动在肝硬化感染相关急性失代偿中的研究
研究纳入391例急性失代偿肝硬化患者,通过高通量蛋白质组学发现并验证感染相关生物标志物。构建的PACIFY模型在验证队列I和II中预测感染的AUC分别为0.965和0.906,外部验证AUC为0.949,决策曲线显示净获益。感染患者中鉴定出516种蛋白质,其中27种上调、38种下调。
要点
- 感染患者白细胞计数、降钙素原、器官衰竭、MELD评分及30天死亡率均较高(P<0.001)。
- PACIFY模型(LGALS3BP+降钙素原+CLIF-COF+乳酸)预测感染优于降钙素原等指标(P<0.001)。
- 蛋白质组学发现感染相关通路包括吞噬功能受损、补体功能异常、低凝、低纤溶等。
核心结论
- 研究识别了与急性失代偿肝硬化感染相关的新蛋白质特征和通路。
- 生物标志物指导的感染治疗可限制不必要的抗菌药物使用并减轻耐药负担。
研究设计与样本
- 研究纳入391例急性失代偿肝硬化患者(92%男性,中位年龄41岁)。
- 发现队列84例(感染54例,非感染30例),验证队列I 147例(感染106例,非感染41例),验证队列II 160例(感染108例,非感染52例)。
- 高通量蛋白质组学在发现队列中鉴定生物标志物,并通过酶联免疫分析在后续队列中验证。
主要发现
- 感染患者白细胞计数、降钙素原、器官衰竭、MELD评分及30天死亡率均较高(P<0.001)。
- 蛋白质组学鉴定516种蛋白质,感染中27种上调、38种下调。
- LGALS3BP、PLTP、CFP和GPX3独立与感染相关(校正严重程度和全身炎症反应综合征后),验证队列I中复合AUC为0.854(95%CI 0.787-0.922)。
- PACIFY模型在验证队列I和II中预测感染的AUC分别为0.965(95%CI 0.933-0.997)和0.906(95%CI 0.860-0.952),优于降钙素原、全身炎症反应综合征、白细胞、中性粒细胞与淋巴细胞比值、中性粒细胞百分比和复合模型(P<0.001)。
- 外部验证AUC为0.949(95%CI 0.916-0.982),决策曲线显示模型在治疗感染和减少不必要抗菌药物使用方面有净获益。
关键数值与推荐
- PACIFY模型包含LGALS3BP、降钙素原、CLIF-COF和乳酸。
- 已开发可部署的应用程序用于感染风险评估。
临床怎么用
- 生物标志物指导的感染治疗可限制不必要的抗菌药物使用并减轻肝硬化中耐药负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inappropriate treatment of infections fuels drug resistance, organ failures, and costs in cirrhosis. We explored proteomics to improve infection diagnosis and management in acutely decompensated (AD) cirrhosis. METHODS: We enrolled 391 patients with AD cirrhosis (92% males, median-age: 41 years), 84 in the discovery cohort (54 infected, 30 non-infected), 147 in the validation cohort I (106 infected, 41 non-infected), and 160 in the validation cohort II (108 infected, 52 non-infected). High-throughput proteomics identified biomarkers in the discovery cohort, validated through enzyme-linked immunoassay in subsequent cohorts. A model for infection was evaluated through discrimination, calibration, and decision curves and was externally validated. RESULTS: Infected patients exhibited higher leucocyte counts, procalcitonin, organ failures, Model for End-stage Liver Disease scores, and 30-day mortality (P < .001 each). Proteomics identified 516 proteins, 27 upregulated and 38 downregulated, in infections. LGALS3BP, PLTP, CFP, and GPX3 were independently linked to infections (adjusting for severity and systemic inflammatory response syndrome), with composite area under the receiver operating characteristic curve (AUC) of 0.854 (95% confidence interval [CI], 0.787-0.922) in validation cohort I. A PACIFY model (LGALS3BP + procalcitonin + CLIF-COF + lactate) predicted infections with AUC of 0.965 (95% CI, 0.933-0.997) and 0.906 (95% CI, 0.860-0.952) in validation cohorts I and II, outperforming procalcitonin, systemic inflammatory response syndrome, white blood cell, neutrophil-to-lymphocyte ratio, neutrophil %, and composite models (P < .001). The model demonstrated fair calibration, with decision curves indicating a net benefit of the model in treating infections and reducing unnecessary antimicrobial use. Consistent findings were observed on external validation (AUC, 0.949; 95% CI, 0.916-0.982), re-enforcing the accuracy and clinical utility of the model. A deployable app was developed for infection risk estimation, enhancing practical applicability. Impaired phagocytosis, complement functions, hypocoagulation, hypofibrinolysis, dysregulated carbohydrate metabolism, autophagy, heightened cell death, and proteolysis were key perturbed pathways in infections. CONCLUSIONS: The study identifies novel protein signatures and pathways linked with infections in AD cirrhosis. A biomarker-guided treatment of infections can limit unnecessary antimicrobial use and the burden of drug resistance in cirrhosis.
引用
- Garg P, Verma N, Valsan A, et al. Proteomics-guided Biomarker Discovery, Validation, and Pathway Perturbation in Infection-related Acute Decompensation of Cirrhosis. Clin Gastroenterol Hepatol. 2025. PMID: 39924007. doi:10.1016/j.cgh.2025.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。